Low-dose aspirin-induced ulceration is attenuated by aspirin- phosphatidylcholine: A randomized clinical trial

American Journal of Gastroenterology

Volumn 106, Issue 2, 2011, Pages 272-277

  Cryer, Byron ^a   Bhatt, Deepak L ^b   Lanza, Frank L ^c   Dong, Jing Fei ^c   Lichtenberger, Lenard M ^d,e   Marathi, Upendra K ^e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e PLx Pharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PL 2200; SALICYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM INJURY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENDOSCOPY; FEMALE; GASTRODUODENAL ULCER; HEARTBURN; HUMAN; HUMAN EXPERIMENT; INCIDENCE; LOW DRUG DOSE; MALE; MULTICENTER STUDY; NAUSEA; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SINGLE BLIND PROCEDURE;

ACUTE DISEASE; ADMINISTRATION, ORAL; AGED; ASPIRIN; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHATIDYLCHOLINES; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; STOMACH ULCER;

EID: 79751528169     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.436     Document Type: Article

References (33)

1. Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
2. Bhatt DL, Steg PG, Ohman EM et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-9. (Pubitemid 43076437)
3. Cannon CP, Rhee KE, Califf RM et al. Current use of aspirin and antithrombotic agents in the United States Among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol 2010; 105: 445-52.
4. Niv Y, Battler A, Abuksis G et al. Endoscopy in asymptomatic minidose aspirin consumers. Dig Dis Sci 2005; 50: 78-80. (Pubitemid 40379143)
5. Yeomans ND, Lanas AI, Talley NJ et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22: 795-801. (Pubitemid 41564359)
6. Goldstein JL, Lowry SC, Lanza FLet al. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective nonsteroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther 2006; 23: 1489-98.
7. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999; 117: 17-25. (Pubitemid 29297615)
8. Hernandez-Diaz S, Garcia Rodriguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med 2006; 4: 22.
9. Moukarbel GV, Signorovitch JE, PfEffer MA et al. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT trial. Eur Heart J 2009; 30: 2226-32.
10. Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-44.
11. Scheiman JM, Yeomans ND, Talley NJ et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101: 701-10.
12. O'Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic Effect and clinical Efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-97.
13. Dial S, Delaney JA, Barkun AN et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium diffi cile-associated disease. JAMA 2005; 294: 2989-95. (Pubitemid 41817660)
14. Yang YX, Lewis JD, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-53. (Pubitemid 46021498)
15. Davenport HW. Damage to the gastric mucosa: Effects of salicylates and stimulation. Gastroenterology 1965; 49: 189-96.
16. Lichtenberger LM, Romero JJ, Dial EJ. Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin. Br J Pharmacol 2007; 150: 913-9. (Pubitemid 46536633)
17. Scheiman JM. NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am 1996; 25: 279-98. (Pubitemid 26161469)
18. Scheiman JM, Kraus ER, Bonnville LA et al. Synthesis and prostaglandin E2-induced secretion of surfactant phospholipid by isolated gastric mucous cells. Gastroenterology 1991; 100: 1232-40.
19. Lichtenberger LM. Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. Biochem Pharmacol 2001; 61: 631-7. (Pubitemid 32239415)
20. Yeomans N, Lanas A, Labenz J et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008; 103: 2465-73.
21. Taha AS, McCloskey C, Prasad R et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 119-25.
22. Lichtenberger LM, Wang ZM, Romero JJ et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med 1995; 1: 154-8.
23. Anand BS, Romero JJ, Sanduja SK et al. Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am J Gastroenterol 1999; 94: 1818-22. (Pubitemid 29315892)
24. Donnelly MT, Goddard AF, Filipowicz B et al. Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury. Aliment Pharmacol Ther 2000; 14: 529-34. (Pubitemid 30240743)
25. Lanza FL, Marathi UK, Anand BS et al. Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic Efficacy in osteoarthritic patients. Aliment Pharmacol Ther 2008; 28: 431-42. (Pubitemid 352033288)
26. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15. (Pubitemid 350106708)
27. Bhatt DL. Intensifying platelet inhibition-navigating between Scylla and Charybdis. N Engl J Med 2007; 357: 2078-81. (Pubitemid 350106717)
28. Wallace JL, McKnight W, Reuter BK et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000; 119: 706-14.
29. Cryer B. Mucosal defense and repair. Role of prostaglandins in the stomach and duodenum. Gastroenterol Clin North Am 2001; 30: 877-94, v-vi. (Pubitemid 33127193)
30. Cryer B, Lapuerta P, Jermano J et al. Omeprazole can prevent the gastroduodenal mucosal injury associated with combined use of clopidogrel and aspirin. Am J Gastroenterol 2008; 103: S38-60.
31. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ (Clinical Research Ed.) 2000; 321: 1183-7.
32. Giuseppe GL, Biondi-Zocci GG, Lotrio M et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006; 27: 2667-74.
33. Abraham NS, El-Serag HB, Johnson ML et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 2005; 129: 1171-8 . (Pubitemid 41446857)